An update of the management of multiple myeloma: the changing landscape.
The management of multiple myeloma is rapidly changing. Cytogenetic, molecular and proteomic techniques have led to a better understanding of the pathophysiology of this heterogeneous malignancy. Novel agents designed to interrupt myeloma growth and survival pathways have entered into clinical usage with unprecedented speed, while new prognostic systems based on clinical and biologic features, such as cytogenetic abnormalities, have been developed. A plethora of clinical trials have been initiated utilizing novel agents, alone or in conjunction with established modalities such as conventional cytotoxic agents and stem cell transplantation. These newer treatments have increased the antitumor response rates in this disease and have provided options for patients whose disease has become resistant to conventional therapy. A major challenge is to define the optimal use of these new agents and combinations in order to significantly impact the natural history of myeloma.
Reece
Donna E
DE
Princess Margaret Hospital, 610 University Ave., Ste. 5-207, Toronto, ON M5G 2M9, Canada. donna.reece@uhn.on.ca
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D003131:Combined Modality Therapy; D006801:Humans; D015994:Incidence; D009101:Multiple Myeloma / Q000453:epidemiology / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D009656:North America / Q000453:epidemiology; D010950:Plasma Cells / Q000473:pathology; D011379:Prognosis; D012008:Recurrence; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents